Health & Biotech
Stories by Tim Boreham
Health & Biotech
Dr Boreham’s Crucible: With new blood at the top, can CSL continue its reign?
Experts
CRITERION: No, these are growth stocks. Literally.
Experts
Dr Boreham’s Crucible: Resmed’s jumped out of bed in 2023
Experts
CRITERION: There’s nothing discrete about this post-lockdown shopping spree
Experts
Tim Boreham’s 20 ASX stocks that are primed to run in 2023 – Part 2
Experts
Tim Boreham’s 20 ASX stocks that are primed to run in 2023 – Part I
Experts
CRITERION: You don’t have to invest in lithium to ride the EV boom
Health & Biotech
The A to Z of Dr Boreham’s Crucible in 2022
Experts
CRITERION: With unemployment at 50-year lows it’s time for these HR stocks to earn their pay
Experts
CRITERION: I allus has wan fruity XPA with coriander notes at 11!
Health & Biotech